ATE470668T1 - Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs - Google Patents

Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs

Info

Publication number
ATE470668T1
ATE470668T1 AT06816244T AT06816244T ATE470668T1 AT E470668 T1 ATE470668 T1 AT E470668T1 AT 06816244 T AT06816244 T AT 06816244T AT 06816244 T AT06816244 T AT 06816244T AT E470668 T1 ATE470668 T1 AT E470668T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
cyclin
pyrazolopyrimidines
cancer
Prior art date
Application number
AT06816244T
Other languages
English (en)
Inventor
Timothy Guzi
Kamil Paruch
Michael Dwyer
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE470668T1 publication Critical patent/ATE470668T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06816244T 2005-10-06 2006-10-04 Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs ATE470668T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/244,772 US7205308B2 (en) 2002-09-04 2005-10-06 Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
PCT/US2006/038838 WO2007044420A1 (en) 2005-10-06 2006-10-04 Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE470668T1 true ATE470668T1 (de) 2010-06-15

Family

ID=37708298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816244T ATE470668T1 (de) 2005-10-06 2006-10-04 Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7205308B2 (de)
EP (1) EP1934224B1 (de)
JP (1) JP2009511483A (de)
CN (1) CN101321757A (de)
AT (1) ATE470668T1 (de)
CA (1) CA2624822A1 (de)
DE (1) DE602006014848D1 (de)
ES (1) ES2345631T3 (de)
WO (1) WO2007044420A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
EP2086644A2 (de) * 2006-11-17 2009-08-12 Schering Corporation Kombination aus einem hemmer der dna-polymerase-alpha und einem hemmer der checkpointkinase zur behandlung von proliferativen erkrankungen
EP2409700A1 (de) 2007-05-08 2012-01-25 Schering Corporation Verfahren zur Behandlung mit intravenösen Formulierungen mit Temozolomid
CA2715815A1 (en) * 2008-02-15 2009-08-20 University Of Southern Mississippi Monomers and polymers with covalently-attached active ingredients
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
EP2419398A4 (de) * 2009-04-14 2012-11-28 Infiniton Ab Prodrug mit beta-keto-carbonsäure, beta-keto-carbonsäuresalz oder beta-keto-carbonsäureester zur wirkstofffreisetzung
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
KR101851130B1 (ko) 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
DK2760867T3 (en) 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014089379A1 (en) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Als atr-kinaseinhibitoren nützliche verbindungen
EP2970288A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Als atr-kinaseinhibitoren nützliche verbindungen
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
EP3236959B1 (de) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (de) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
EP3355926B1 (de) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Kombination von dna-schädigenden mitteln und atr-inhibitoren zur verwendung in einem verfahren zur behandlung von krebs
EP3377908B1 (de) 2015-11-18 2020-08-05 Genzyme Corporation Biomarker von polyzystischer nierenkrankheit und verwendungen davon
JP7216705B2 (ja) * 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
WO2019197549A1 (en) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
WO2019222509A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Pyrazolopyrimidines as mertk inhibitors and their application in cancer treatment
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
JP7628252B2 (ja) * 2019-02-01 2025-02-10 ユニヴァーシティー オブ サウスカロライナ 二環式ピリジン組成物およびがんの治療にそれを使用する方法
CN111393447B (zh) * 2020-05-14 2021-01-15 苏州信诺维医药科技有限公司 一种嘧啶并吡唑类化合物、其制备方法及应用
EP4282868B1 (de) * 2021-01-22 2026-03-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituiertes pyrazolo[1,5-a pyrimidin-7-aminderivat und zusammensetzungen und medizinische verwendung davon
CN116693538A (zh) * 2022-03-04 2023-09-05 成都苑东生物制药股份有限公司 一种吡唑并嘧啶类衍生物、其制备方法及用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585462B2 (ja) 1989-10-25 1997-02-26 株式会社大塚製薬工場 ピラゾロ［１，５―ａ］ピリミジン誘導体
EP0591528B1 (de) 1991-04-22 1998-12-23 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
EP0628559B1 (de) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidinverbindungen und ihre Verwendung als Pharmazeutika
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
GB9325074D0 (en) * 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
EP0714898B1 (de) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a] PYRIMIDIN-DERIVATE
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6282096B1 (en) * 2000-04-28 2001-08-28 Siliconware Precision Industries Co., Ltd. Integration of heat conducting apparatus and chip carrier in IC package
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
JP2004528295A (ja) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド キナーゼ阻害方法
DE60302150D1 (en) 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TWI335919B (en) * 2002-09-04 2011-01-11 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN1701073B (zh) * 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1599482A4 (de) * 2003-02-28 2008-10-01 Teijin Pharma Ltd Pyrazolo¬1,5-a pyrimidinderivate
EP1608652A1 (de) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidinverbindungen und deren verwendung in der medizin
EP1661897B1 (de) * 2003-08-26 2013-12-04 Teijin Pharma Limited Pyrrolopyrimidinonderivat
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors

Also Published As

Publication number Publication date
HK1112233A1 (en) 2008-08-29
WO2007044420A1 (en) 2007-04-19
CA2624822A1 (en) 2007-04-19
EP1934224A1 (de) 2008-06-25
ES2345631T3 (es) 2010-09-28
DE602006014848D1 (de) 2010-07-22
EP1934224B1 (de) 2010-06-09
US20060041131A1 (en) 2006-02-23
CN101321757A (zh) 2008-12-10
US7205308B2 (en) 2007-04-17
JP2009511483A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
ATE470668T1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhängiger kinase zur behandlung von krebs
BRPI0314001B8 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
WO2007044449A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY141978A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
WO2007032936A3 (en) Azafused cyclin dependent kinase inhibitors
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
TH148526B (th) ไพราโซโลไพริมิดีนชนิดใหม่ (Novel pyrazolopyrimidines) ล่าสุดในฐานะตัวยับยั้งไซคลินดีเพนเดนท์คิเนส (Cyclin dependent kinase inhibitors)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties